Shares of Neuroderm Ltd (NASDAQ:NDRM) have earned a consensus recommendation of “Hold” from the seven analysts that are currently covering the stock. Four investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $48.33.
Several equities analysts recently weighed in on NDRM shares. Citigroup Inc cut shares of Neuroderm from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 7th. Zacks Investment Research cut shares of Neuroderm from a “buy” rating to a “hold” rating in a research note on Wednesday, April 5th. Roth Capital set a $33.00 target price on shares of Neuroderm and gave the company a “buy” rating in a research note on Thursday, March 2nd. Oppenheimer Holdings Inc. reaffirmed a “market perform” rating on shares of Neuroderm in a research note on Tuesday, March 7th. Finally, Cowen and Company raised their target price on shares of Neuroderm from $38.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday, March 1st.
COPYRIGHT VIOLATION NOTICE: “Neuroderm Ltd (NDRM) Receives Average Recommendation of “Hold” from Brokerages” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/04/21/analysts-set-neuroderm-ltd-ndrm-pt-at-44-25-updated.html.
Institutional investors have recently modified their holdings of the company. Scopia Capital Management LP acquired a new position in shares of Neuroderm during the third quarter worth approximately $62,558,000. Franklin Resources Inc. acquired a new position in shares of Neuroderm during the fourth quarter worth approximately $11,100,000. Baker BROS. Advisors LP purchased a new stake in Neuroderm during the third quarter valued at about $5,639,000. Adage Capital Partners GP L.L.C. purchased a new stake in Neuroderm during the third quarter valued at about $5,122,000. Finally, Acuta Capital Partners LLC raised its stake in Neuroderm by 43.8% in the fourth quarter. Acuta Capital Partners LLC now owns 665,944 shares of the biotechnology company’s stock valued at $14,784,000 after buying an additional 202,988 shares during the period. 35.09% of the stock is owned by institutional investors and hedge funds.
Shares of Neuroderm (NASDAQ:NDRM) traded down 0.92% during trading on Tuesday, reaching $26.90. The company’s stock had a trading volume of 395,115,693 shares. Neuroderm has a 12 month low of $15.10 and a 12 month high of $30.45. The firm’s market cap is $708.49 million. The stock’s 50 day moving average price is $26.79 and its 200-day moving average price is $22.18.
Neuroderm (NASDAQ:NDRM) last posted its earnings results on Thursday, March 30th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.03. Equities analysts predict that Neuroderm will post ($1.87) EPS for the current year.
Neuroderm Company Profile
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for Neuroderm Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuroderm Ltd and related companies with MarketBeat.com's FREE daily email newsletter.